Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 to Patients with Advanced Solid Tumors

NCT03604783 is registered in ClinicalTrials.gov with Sumitomo Pharma America, Inc. as lead sponsor.

NCT NCT03604783
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03604783 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 to Patients with Advanced Solid Tumors
Lead sponsor
Sumitomo Pharma America, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
December 26, 2018
Completion date
January 10, 2024
Enrollment
74 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, dedifferentiated liposarcoma, ewing sarcoma, sarcoma, synovial sarcoma